Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma

References

• Eifel PJ, Ross J, Hendrickson M, Cox RS, Kempson R, Martinez A. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 1983; 52: 1026–31.
   Google Scholar
• Webb GA, Lagios MD. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol 1987; 156: 1486–91.
   Google Scholar
• Wilson TO, Podratz KC, Gaffey TA, Malkasian GD, O’Brien PC, Naessens JM. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990; 162: 418–26.
   Google Scholar
• Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathologic study of 22 cases. Gynecol Oncol 1990; 39: 266–71.
   Google Scholar
• Greven KM, Lanciano RM, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 1993; 71: 3697–702.
   Google Scholar
• Lampe B, Kurzl R, Hantschmann P Prognostic factors that predict pelvic lymph node metastasis from endometrial carcinoma. Cancer 1994; 74: 2502–8.
   Google Scholar
• Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54: 264–8.
   Google Scholar
• Grice J, Ek M, Greer B, Koh W-J, Muntz HG et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998; 69: 69–73.
   Google Scholar
• Clement PB, Scully RE. Endometrial hyperplasia and carcinoma. In: Clement PB, Young RH, eds. Tumors and tumorlike lesions of the uterine corpus and cervix. New York: Churchill Livingstone, 1993: 181–264.
   Google Scholar
• FIGO (International Federation of Gynecology and Obstetrics), FIGO News, Corpus cancer staging. Int J Gynaecol Obstet 1989; 28: 189–93.
   Google Scholar
• Kurman RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, Norris HJ, eds. Blaustein’s pathology of the female genital tract. 3rd ed. New York: Springer, 1987: 338–72.
   Google Scholar
• Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981; 105: 615–18.
   Google Scholar
• Hendrickson MR, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93–108.
   Google Scholar
• Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol 1985; 4: 279–88.
   Google Scholar
• Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol 1986; 67: 670–4.
   Google Scholar
• Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol Oncol 1987; 27: 294–304.
   Google Scholar
• Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol 1987; 69: 109–13.
   Google Scholar
• Ramirez-Gonzalez CE, Adamsons K, Mangual-Vazquez TY, Wallach RC. Papillary adenocarcinoma in the endometrium. Obstet Gynecol 1987; 70: 212–15.
   Google Scholar
• Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases. Am J Clin Pathol 1982; 77: 534–40.
   Google Scholar
• Descamps P, Calais G, Moire C, Bertrand P, Castiel M, Le Floch O et al. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol 1997; 64: 54–8.
   Google Scholar
• Malpica A, Tornos C, Burke TW, Silva EG. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995; 19: 769–74.
   Google Scholar
• Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61: 167–74.
   Google Scholar
• Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22: 1463–73.
   Google Scholar
• Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994; 74: 1778–83.
   Google Scholar
• Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29: 551–8.
   Google Scholar
• Bancher-Todesca D, Neuteufel W, Williams KE, Prainsack D, Breitenecker G, Friedlander ML et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998; 71: 3447.
   Google Scholar
• Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999; 74: 272–7.
   Google Scholar
• Price FV, Amin RM, Sumkin J. Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma. Gynecol Oncol 1999; 73: 140–4.
   Google Scholar
• Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 1999; 73: 461–3.
   Google Scholar